NCT00082563TerminatedPhase 2
A Phase II, Randomized, Comparative Trial Of Azithromycin In Combination With Chloroquine Versus Chloroquine In The Eradication Of Asymptomatic Plasmodium Falciparum Infection In Semi-Immune Adults
Conditions
Drugs
Trial Snapshot
- Phase
- Phase 2
- Status
- Terminated
- Sponsor
- Pfizer
- Enrollment
- 14
- Primary Endpoint
- Parasite clearance
Study Overview
Brief Summary
The purpose of this study is to determine if Azithromycin in combination with chloroquine is superior to chloroquine alone in eradicating P. falciparum asexual parasitemia in asymptomatic, semi-immune adults in Western Kenya.
Detailed Description
The trial was terminated prematurely 9 November 2004 due to the inability to recruit the planned number of subjects. There were no safety or efficacy concerns regarding the study in the decision to terminate the trial.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- Double
Eligibility Criteria
- Ages
- 18 Years to 60 Years (Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Healthy adult: male or female
- •Asymptomatic mono-infection with P. falciparum parasitemia with a parasite density of 1000 - 30,000 parasites/μL
- •Age 18 years to 60 years
- •Willingness to sign and ability to understand consent form
- •Willingness and ability to return for scheduled follow up visits
Exclusion Criteria
- •Mixed malaria infection by Giemsa smear
- •History of allergy to or hypersensitivity to chloroquine, Azithromycin or other macrolides (e.g. erythromycin, clarithromycin)
- •Any of the following: a.) Antimalarial therapy administered in the past 4 weeks, including quinine therapy or an artemisinin derivative; or b.) An antibacterial with known antimalarial activity (including, erythromycin, doxycycline, clindamycin, cotrimoxazole) within one week prior to enrollment into the study
- •Fever, history of fever in past 48 hours, or signs/symptoms of malaria (including acute or subacute headache, nausea, or vomiting)
- •Inability to swallow oral medication
- •Laboratory evidence or history of significant cardiovascular, liver, hematologic or renal functional abnormality
- •Any situation which could prevent the patient from returning to follow up visits
- •Pregnancy or breast feeding
- •Any other concurrent illness that may confound the result
- •Any other condition or circumstance that in the opinion of the Investigator may pose a threat to the study participant or study
Outcomes
Primary Outcomes
Parasite clearance
Secondary Outcomes
- tolerability
Investigators
Similar Trials
Completed
Phase 2
Azithromycin Plus Chloroquine Versus Mefloquine for the Treatment of Uncomplicated Malaria in AfricaMalaria, FalciparumNCT00082576Pfizer238
Completed
Phase 2
Azithromycin Plus Chloroquine Versus Atovaquone-Proguanil For The Treatment Of Uncomplicated Plasmodium Falciparum Malaria In South AmericaMalaria, FalciparumNCT00084227Pfizer244
Completed
Phase 2
Trial of Azithromycin Plus Chloroquine Versus Sulfadoxine-Pyrimethamine Plus Chloroquine for the Treatment of Uncomplicated Malaria in IndiaPLASMODIUM FALCIPARUM MALARIANCT00074841Pfizer230
Completed
Phase 2
Azithromycin Plus Chloroquine Versus Artemether-Lumefantrine For The Treatment Of Uncomplicated P. Falciparum Malaria In Children In AfricaMalaria, FalciparumNCT00677833Pfizer361
Terminated
Phase 2
Randomized Comparison of Combination Azithromycin and Hydroxychloroquine vs. Hydroxychloroquine Alone for the Treatment of Confirmed COVID-19SARS-CoV-2COVID-19NCT04336332Rutgers, The State University of New Jersey75